Business description: Kenvue Inc.

Kenvue Inc. is one of the world leaders in the design, manufacture and marketing of consumer healthcare products. The group offers products for health, beauty, baby care, oral care, skin care and more. Net sales break down by family of products as follows:

- self care products (41,8%): for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.);

- personal care products (29.9%): primarily oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.);

- beauty and skin care products (28.3%): hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.).

Product marketing is assured through direct sales, distributors and the Internet.

Net sales are distributed geographically as follows: North America (49.3%), Europe-Middle East-Africa (21.9%), Asia-Pacific (20.1%) and Latin America (8.7%).

Number of employees: 22,000

Sales by Activity: Kenvue Inc.

Fiscal Period: December20192020202120222023

Self Care

4.82B 5.24B 5.64B 6.03B 6.45B

Essential Health

4.9B 4.78B 4.87B 4.57B 4.62B

Skin Health and Beauty

4.61B 4.45B 4.54B 4.35B 4.38B
See all business segments

Geographical breakdown of sales: Kenvue Inc.

Fiscal Period: December20192020202120222023

North America

6.51B 7.1B 7.28B 7.42B 7.61B

Europe, Middle East, and Africa

3.46B 3.33B 3.44B 3.19B 3.39B

Asia-Pacific

3.08B 3.01B 3.28B 3.15B 3.11B

Latin America

1.28B 1.03B 1.06B 1.2B 1.34B
See all geographic segments

Managers: Kenvue Inc.

Director TitleAgeSince
Chief Executive Officer 54 2023-05-07
Director of Finance/CFO - 2023-04-30
Chief Tech/Sci/R&D Officer 52 2023-04-30
Chief Tech/Sci/R&D Officer 56 2023-04-30
Chief Operating Officer 61 2023-04-30
See KENVUE INC. governance

Members of the board: Kenvue Inc.

Manager TitleAgeSince
Director/Board Member 54 2023-05-07
Chairman 68 2023-04-30
Director/Board Member 64 2023-05-03
Director/Board Member 57 2023-05-07
Director/Board Member 54 2023-05-07
Director/Board Member 63 2023-05-07
Director/Board Member 68 2023-05-07
Director/Board Member 65 2023-05-07
Director/Board Member 57 2023-05-07
Director/Board Member 64 2024-08-14
Composition of the Board of Directors

Shareholders: Kenvue Inc.

NameEquities%Valuation
T. Rowe Price International Ltd.
12.41 %
237,674,170 12.41 % 5 450 M $
Vanguard Fiduciary Trust Co.
11.33 %
216,906,964 11.33 % 4 974 M $
Fidelity Management & Research Co. LLC
7.201 %
137,915,493 7.201 % 3 162 M $
127,213,940 6.642 % 2 917 M $
BlackRock Advisors LLC
5.449 %
104,349,055 5.449 % 2 393 M $
List of KENVUE INC. shareholders

Company details: Kenvue Inc.

Kenvue, Inc.

199 Grandview Road

08558, Skillman

+908 874 1200

http://www.kenvue.com
address Kenvue Inc.(KVUE)

Group companies: Kenvue Inc.

NameCategory and Sector
Pharmaceuticals: Major
See all subsidiaries

Other Personal Products

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.13%-4.14%+14.68% - 44.35B
+0.53%-1.86%+19.94%+17.45%415B
+0.03%-0.66%+22.80%+18.92%147B
+0.31%-1.72%+22.43%+23.88%77.7B
-0.35%-0.48%-3.19%+7.65%69.13B
+2.54%+1.79%-5.24%+39.06%28.9B
-1.41%+5.69%-40.86%-76.69%28.06B
+0.16%+3.20%+17.44%+6.83%19.75B
-0.75%-0.74%+18.94%+39.33%15.03B
+0.12%-0.64%-4.77%-7.67%10.94B
Average +0.08%-0.31%+6.22%+7.64% 85.58B
Weighted average by Cap. +0.18%-1.26%+15.28%+14.82%
See all sector performances
Trading Rating
Investor Rating
ESG Refinitiv
surperformance-ratings-light-chart KENVUE-INCMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
23.13USD
Average target price
24.68USD
Spread / Average Target
+6.71%
Consensus

Quarterly revenue - Rate of surprise